AUS
NZ
UK
CA
USA
IND
Healthcare
ASX 100 Healthcare Giant: Why COH Shares Are Under Spotlight
April 16, 2026 10:04 AM AEST| By SamCochlear shares are under focus after a pullback, with healthcare resilience, global demand, and valuation dynamics shaping its outlook as a key ASX 100 medical technology company.
Is Lumos Diagnostics (ASX:LDX) Shaping ASX All Ordinaries Healthcare Landscape?
April 15, 2026 06:04 PM AEST| By SamLumos Diagnostics outlines reporting plans and investor engagement while advancing its share purchase plan, reflecting continued activity within the healthcare diagnostics sector.
All Ordinaries Spotlight: Orthocell Expands Remplir Access
April 15, 2026 01:06 PM AEST| By SamOrthocell expanded access to US military and veterans hospitals, advancing Remplir distribution and strengthening its presence in the global healthcare sector.
SHL Under Pressure: Hidden Opportunity in ASX 100 Healthcare?
April 15, 2026 10:41 AM AEST| By SamSonic Healthcare’s valuation and global presence highlight a defensive yet growth-oriented profile, with healthcare demand stability and international expansion shaping its outlook despite recent share price weakness.
Telix Bond Boost: Is ASX 100 Healthcare Story Resetting?
April 15, 2026 10:27 AM AEST| By SamTelix upsized its bond offering, strengthening financial flexibility and refining its capital structure, with future performance linked to clinical execution and global expansion in the healthcare sector.
Ryman Healthcare Sales Rise Despite Network Changes
April 15, 2026 10:13 AM AEST| By SamRyman Healthcare reported steady Q4 sales growth supported by strong occupancy and serviced apartment demand, maintaining resilience despite village closures and broader economic uncertainty affecting global markets.
Can PainChek’s US Deal Redefine Aged Care Tech?
April 14, 2026 06:33 PM AEST| By SamPainChek strengthens global presence through a US partnership, advancing AI-based pain assessment adoption across aged care facilities while scaling its reach in healthcare technology markets.
Is Entropy Neurodynamics Driving All Ords with Trial Gains?
April 14, 2026 05:07 PM AEST| By SamEntropy Neurodynamics advances clinical research with TRP program development, controlled infusion methods, and strengthened funding within the ASX healthcare sector.
Could This ASX Biotech Be Gearing Up for a Key Breakthrough?
April 14, 2026 04:53 PM AEST| By SamPercheron Therapeutics advances its oncology program with fresh funding, supporting clinical progress and upcoming research milestones in the evolving biotech landscape.
Can FebriDx Drive Lumos Diagnostics’ US Expansion?
April 14, 2026 04:46 PM AEST| By SamLumos Diagnostics accelerates FebriDx adoption across US urgent care centres, strengthening its commercial presence and supporting faster clinical decision-making in respiratory care.
Could Jupiter Unlock a New Rare Earths Breakthrough?
April 14, 2026 04:27 PM AEST| By SamCritica’s Jupiter project shows encouraging rare earth recovery progress, with advancing studies and optimisation efforts supporting future development in Western Australia’s resource sector.
Could Psychedelic Science Redefine Binge Eating Treatment?
April 14, 2026 04:23 PM AEST| By SamA clinical update highlights advancements in psychedelic therapy for binge eating disorder, showcasing controlled treatment methods, ongoing trials, and growing interest in innovative mental health solutions.
Aroa Biosurgery Gains as All Ordinaries Sees Healthcare Growth
April 14, 2026 04:00 PM AEST| By SamAroa Biosurgery operates within the healthcare sector using ECM technology, maintaining a debt-free structure while expanding commercial activity and reducing financial losses.
Can Percheron’s Fresh Funding Drive Its Cancer Therapy Forward?
April 14, 2026 02:39 PM AEST| By SamPercheron advances its cancer therapy with fresh funding, setting up the next clinical phase while drawing attention through upcoming research presentations and strategic progress.
All Ordinaries Healthcare Stocks US Market Expansion Focus
April 14, 2026 12:10 PM AEST| By SamHealthcare sector activity highlights milestone payments and international expansion, reflecting continued commercial progress in diagnostic technology within the All Ordinaries index.
How Orthocell Limited (ASX:OCC) Fits in ASX 300 Healthcare Sector Trends
April 14, 2026 11:30 AM AEST| By SamOrthocell prepares quarterly update and investor webinar, reflecting healthcare sector activity and biotechnology development within Australian equity markets.
ASX 200 Healthcare Stock (ASX:TLX): How Telix’s Regeneron Deal and FDA Progress Are Reshaping Its Growth Narrative
April 14, 2026 10:51 AM AEST| By SamTelix Pharmaceuticals gains momentum after a Regeneron partnership and FDA milestone, strengthening its transition toward a multi-product oncology platform, though execution risks and reliance on imaging revenues remain key considerations.
Telix (ASX:TLX) Signals Fresh Growth Trajectory Amid Expanding Footprint
April 13, 2026 03:36 PM AEST| By Team Kalkine MediaTelix Pharmaceuticals advances its oncology strategy through a major collaboration and regulatory milestone, strengthening its radiopharmaceutical platform and expanding its presence beyond core imaging markets.
Is Monash IVF Near a Deal as Takeover Pressure Builds?
April 13, 2026 03:29 PM AEST| By SamMonash IVF reviews a revised takeover proposal as investor interest grows, highlighting valuation debates, sector demand trends, and strategic decisions shaping the company’s future.
Small Move, Big Signal? Syntara’s ASX Update Explained
April 13, 2026 10:53 AM AEST| By SamSyntara has applied to list new shares on the ASX, reflecting routine capital management activity that slightly expands its equity base while improving liquidity and maintaining transparency.
Advertise your brand on Kalkine Media